UBQ4 Antibody

What is UBQLN4 and why is it significant in research?

UBQLN4 is a protein involved in the ubiquitin-proteasome pathway that has been implicated in cancer progression. Research has demonstrated that UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer (NSCLC) cells by activating the PI3K/AKT pathway. Studies show UBQLN4 is upregulated in NSCLC tissues and cell lines, and high expression correlates with poorer patient survival outcomes. This makes UBQLN4 a significant target for cancer research, with potential implications for therapeutic development and prognostic assessment .

What types of UBQLN4 antibodies are available for research?

Researchers can access various types of UBQLN4 antibodies, including monoclonal antibodies like the rabbit mAb produced by immunizing animals with synthetic peptides corresponding to specific regions of human UBQLN4 protein. For example, the E7N4Q clone targets residues surrounding Lys87 of human UBQLN4. These antibodies are available for applications including Western blotting and immunoprecipitation, with validated reactivity against human, mouse, and rat samples .

How does UBQLN4 function at the molecular level?

UBQLN4 functions within the ubiquitin-proteasome system and influences cellular proliferation and invasion pathways. Mechanistic studies reveal that UBQLN4 activates the PI3K/AKT signaling pathway, a crucial regulator of cell survival and growth. Additionally, UBQLN4 has been shown to enhance epithelial-mesenchymal transition (EMT), a process where epithelial cells lose their adhesive properties and gain mesenchymal characteristics, facilitating cancer cell invasion and metastasis. This is evidenced by altered expression of epithelial markers (E-cadherin) and mesenchymal markers (N-cadherin and vimentin) in response to UBQLN4 expression changes .

What are the validated applications for UBQLN4 antibodies?

UBQLN4 antibodies have been validated for several research applications, primarily Western blotting and immunoprecipitation. The recommended dilution ratios are specific to each application, with Western blotting typically performed at 1:1000 dilution and immunoprecipitation at 1:50. These applications allow researchers to detect and analyze endogenous UBQLN4 protein in various experimental contexts, including cancer cell lines and tissue samples .

How should researchers design experiments to assess UBQLN4 function in cancer cells?

To investigate UBQLN4 function in cancer cells, researchers should consider both loss-of-function and gain-of-function approaches. Based on published methodologies, a comprehensive experimental design would include:

• Genetic manipulation: Use lentiviral-mediated shRNA for silencing UBQLN4 expression and lentiviral-mediated overexpression vectors (e.g., plvx-UBQLN4) for increased expression.

• Validation of manipulation: Confirm altered expression using both qRT-PCR and Western blotting to verify changes at both mRNA and protein levels.

• Functional assays: Employ cell proliferation assays (CCK-8), colony formation assays, and cell invasion assays to measure the impact of UBQLN4 alteration.

• Molecular pathway analysis: Examine EMT markers (E-cadherin, N-cadherin, vimentin) and PI3K/AKT pathway components via Western blotting.

• In vivo validation: Consider xenograft models to confirm in vitro findings in a more physiologically relevant context .

What controls should be included when using UBQLN4 antibodies?

When using UBQLN4 antibodies, researchers should implement a comprehensive set of controls to ensure reliable and interpretable results:

• Positive control: Include samples known to express UBQLN4, such as NSCLC cell lines (H520, H1299, A549, H358) that have been shown to express high levels of the protein.

• Negative control: Include samples with low UBQLN4 expression, such as normal bronchial/tracheal epithelial cell lines (HBE).

• Knockdown/knockout validation: Use samples with UBQLN4 knockdown or knockout to confirm antibody specificity.

• Loading control: Include appropriate housekeeping proteins for normalization in Western blot experiments.

• Secondary antibody-only control: To detect any non-specific binding of the secondary antibody .

How should researchers validate the specificity of UBQLN4 antibodies?

Validating antibody specificity is critical for reliable research outcomes. For UBQLN4 antibodies, a comprehensive validation approach should include:

• Genetic manipulation controls: Test antibody on samples with knockdown or overexpression of UBQLN4 to confirm that signal strength correlates with expression level.

• Multiple detection methods: Verify findings using alternative techniques (e.g., IF, IHC, Western blot) to ensure consistent detection.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to block specific binding and confirm signal reduction.

• Cross-reactivity testing: Assess reactivity with related proteins to ensure specificity for UBQLN4.

• Multiple antibody validation: Use more than one antibody targeting different epitopes of UBQLN4 to confirm findings.

This multi-layered approach is essential for establishing antibody specificity and reliability, following principles similar to those used in developing site-specific ubiquitin antibodies .

What are the key steps in developing site-specific antibodies against ubiquitinated proteins?

Developing site-specific antibodies against ubiquitinated proteins involves a systematic process:

• Design and synthesis of non-hydrolyzable ubiquitin-peptide conjugates for immunization. These conjugates should mimic the native ubiquitination site but be resistant to deubiquitinating enzymes.

• Design and synthesis of extended native isopeptide-linked ubiquitin-peptide conjugates for screening, typically extending the peptide by two amino acids at N/C termini to better mimic the native protein context.

• Immunization of animals, usually mice, followed by generation and selection of hybridomas producing antibodies.

• Comprehensive screening protocols, including ELISA with the target conjugate, native peptide, and ubiquitin alone to identify truly site-specific antibodies.

• Validation through immunoblot analysis with recombinant proteins, including critical negative controls such as non-modified protein, free ubiquitin, and independent ubiquitinated proteins .

How can researchers distinguish between site-specific antibodies and non-specific ubiquitin antibodies?

Distinguishing site-specific ubiquitin antibodies from non-specific ones requires careful screening:

• ELISA screening using multiple substrates:

  • The ubiquitinated target peptide/protein

  • The non-ubiquitinated peptide/protein

  • Free ubiquitin

  • Different ubiquitinated proteins

• Immunoblot validation using:

  • Recombinant proteins enzymatically ubiquitinated at specific sites

  • Wild-type proteins vs. mutants where the ubiquitination site is altered

  • Cell lysates from conditions known to induce or reduce site-specific ubiquitination

• Specificity verification using multiple controls:

  Sample Type	Expected Result for Site-Specific Antibody	Expected Result for Non-Specific Antibody
  Target protein-Ubiquitin	Strong signal	Signal present
  Different protein-Ubiquitin	No signal	Signal present
  Free ubiquitin	No signal	Possible signal
  Non-ubiquitinated target	No signal	No signal

This multi-layered screening approach is essential, as evidenced by difficulties encountered in developing PCNA-K164ub antibodies, where initial promising clones demonstrated lack of specificity in subsequent validation steps .

How should researchers interpret contradictory results with UBQLN4 antibodies?

When faced with contradictory results using UBQLN4 antibodies, researchers should systematically troubleshoot by:

• Verifying antibody quality: Check for lot-to-lot consistency, proper storage conditions, and potential degradation. Recombinant antibodies often provide superior consistency compared to traditional antibodies .

• Evaluating experimental conditions: Optimize protein extraction methods, blocking buffers, incubation times, and washing steps. Different tissues or cell types may require adjusted protocols.

• Assessing target protein modifications: Consider whether post-translational modifications or protein complexes might mask the epitope in certain conditions.

• Using orthogonal validation methods: Confirm findings using alternative techniques such as mass spectrometry or proximity ligation assays.

• Cross-referencing with existing literature: Situate your findings within the broader research context to identify potential biological or technical explanations for discrepancies.

• Implementing genetic approaches: Use CRISPR/Cas9 or siRNA knockdown controls to definitively establish signal specificity .

What factors influence the reliability of Western blot results with UBQLN4 antibodies?

Multiple factors can influence Western blot reliability when using UBQLN4 antibodies:

• Sample preparation: Incomplete protein denaturation, insufficient lysis, or degradation can affect target detection. UBQLN4 has been observed at approximately 75 kDa in Western blots, but degradation products may appear at lower molecular weights .

• Transfer efficiency: Inadequate transfer, particularly of high molecular weight proteins, can result in inconsistent detection.

• Blocking conditions: Insufficient blocking or inappropriate blocking agents can lead to high background or reduced specific signal.

• Antibody dilution: The recommended 1:1000 dilution for Western blotting should be optimized for each experimental system .

• Species cross-reactivity considerations: While the E7N4Q UBQLN4 antibody shows reactivity with human, mouse, and rat samples, the strength of detection may vary between species .

• Detection method sensitivity: Chemiluminescence, fluorescence, and colorimetric detection systems vary in sensitivity and dynamic range, potentially affecting result interpretation.

How can researchers address non-specific binding issues with UBQLN4 antibodies?

To address non-specific binding issues with UBQLN4 antibodies, researchers should:

• Optimize blocking conditions: Test different blocking agents (BSA, non-fat dry milk, commercial blocking buffers) and concentrations to reduce background.

• Increase washing stringency: Implement additional wash steps or include detergents like Tween-20 at appropriate concentrations to reduce non-specific interactions.

• Titrate antibody concentration: Test multiple dilutions beyond the recommended 1:1000 for Western blotting to determine the optimal concentration that maximizes specific signal while minimizing background .

• Pre-absorb antibody: Incubate the antibody with lysate from cells lacking the target protein or with the sample that gives excessive background.

• Use alternative detection systems: Switch between HRP-conjugated, fluorescent, or other detection methods to determine if the issue is related to the detection system rather than the primary antibody.

• Verify epitope accessibility: Ensure that sample processing methods do not alter the epitope surrounding Lys87 of human UBQLN4 protein that is targeted by the E7N4Q antibody .

How can researchers utilize UBQLN4 antibodies to investigate its role in the PI3K/AKT pathway?

To investigate UBQLN4's role in the PI3K/AKT pathway, researchers should implement a multi-faceted experimental approach:

• Co-immunoprecipitation studies: Use UBQLN4 antibodies to identify binding partners within the PI3K/AKT pathway, potentially revealing direct interactions or complex formations.

• Proximity ligation assays: Employ UBQLN4 antibodies alongside antibodies against PI3K/AKT pathway components to visualize and quantify protein-protein interactions in situ.

• Phosphorylation state analysis: After UBQLN4 manipulation (knockdown or overexpression), use phospho-specific antibodies to assess the activation state of key PI3K/AKT pathway proteins.

• Pathway inhibitor studies: Combine UBQLN4 overexpression with specific inhibitors of the PI3K/AKT pathway to determine whether UBQLN4's effects on cell proliferation and invasion are dependent on this pathway.

• Domain mapping: Use truncated UBQLN4 constructs and corresponding antibodies to identify which domains of UBQLN4 are essential for PI3K/AKT pathway activation .

What are the emerging applications of computational methods in improving antibody design and specificity?

Computational methods are increasingly valuable for antibody design and specificity enhancement:

• Loop structure prediction: Advanced computational models can now predict antibody loop structures with high accuracy, enabling zero-shot design of target-binding antibody loops. This approach permits the design of antibodies with high affinity, diversity, and specificity without requiring extensive experimental screening .

• Epitope mapping and optimization: Computational analysis can identify optimal epitopes on target proteins, predicting which regions will elicit the most specific and highest-affinity antibodies.

• Cross-reactivity prediction: Algorithms can scan proteomes to identify potential cross-reactive targets, allowing researchers to design antibodies with minimized off-target binding.

• Stability enhancement: Computational methods can predict mutations that improve antibody stability and expression levels without compromising binding specificity.

• Integration with experimental data: Combined computational-experimental approaches leverage machine learning to iteratively improve antibody design based on experimental feedback .

How might UBQLN4 research contribute to understanding broader ubiquitin pathway dysregulation in cancer?

UBQLN4 research offers significant insights into ubiquitin pathway dysregulation in cancer:

• Integration with other ubiquitin-related proteins: Studies using UBQLN4 antibodies can help map interactions with other ubiquitin-related proteins, potentially revealing coordinated dysregulation patterns in cancer.

• Identification of novel therapeutic targets: Understanding UBQLN4's role in the PI3K/AKT pathway and EMT may highlight new intervention points for cancer therapy, particularly in tumors with ubiquitin system alterations.

• Biomarker development: UBQLN4 expression patterns, detected using specific antibodies, could serve as prognostic or predictive biomarkers for patient stratification, given the correlation between high UBQLN4 expression and poor survival in NSCLC patients .

• Mechanistic understanding of treatment resistance: Investigation of UBQLN4's role in cancer cell survival and proliferation may explain resistance to certain therapies and suggest combination approaches.

• Systems-level insights: Integration of UBQLN4 data with other "omics" datasets would provide a more comprehensive understanding of how ubiquitin pathway components collectively contribute to cancer progression, similar to approaches used in studying host-pathogen interactions .